Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2388-2406

  Toogood, Peter L ^a   Harvey, Patricia J ^a   Repine, Joseph T ^a   Sheehan, Derek J ^a   VanderWel, Scott N ^a   Zhou, Hairong ^a   Keller, Paul R ^a   McNamara, Dennis J ^a   Sherry, Debra ^a   Zhu, Tong ^a   Brodfuehrer, Joanne ^a   Choi, Chung ^a   Barvian, Mark R ^a   Fry, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PD 0332991; PYRIDO[2,3 D]PYRIMIDIN 7 ONE DERIVATIVE; PYRIMIDINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; G1 PHASE; HUMANS; MALE; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 20244365948     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049354h     Document Type: Article

References (96)

1. (a) Fisher, P. M.; Gianella-Borradori, A. CDK Inhibitors in Clinical Development for the Treatment of Cancer. Expert. Opin. Investig. Drugs 2003, 12, 955-970.
2. (b) Huwe, A.; Mazitschek, R.; Giannis, A. Small Molecules as Inhibitors of Cyclin-Dependent Kinases. Angew. Chem., Int. Ed. 2003, 42, 2122-2138.
3. (c) Sherr, C. J.; McCormick, F. The Rb and p53 Pathways in Cancer. Cancer Cell 2002, 2, 103-112.
4. (d) Fisher, P. M. Recent Advances and New Directions in the Discovery and Development of Cyclin-Dependent Kinase Inhibitors. Curr. Opin. Drug Discuss. Dev. 2001, 4, 623-634.
5. (e) Webster, K. R.; Kimball, S. D. Novel Drugs Targeting the Cell Cycle. Emerging Drugs 2000, 5, 45-59.
6. (f) Fry, D. W.; Garrett, M. D. Inhibitors of Cyclin-Dependent Kinases as Therapeutic Agents for the Treatment of Cancer. Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs 2000, 2, 40-59.
7. (g) Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. J. Med. Chem. 2000, 43, 1-18.
8. (h) Mani, S.; Wang, C.; Wu, K.; Francis, R.; Pestell, R. Cyclin-Dependent Kinase Inhibitors: Novel Anticancer Agents. Exp. Opin. Invest. Drugs 2000, 9, 1849-1870.
9. (i) Rosania, G. R.; Chang, Y.-T. Targeting Hyperproliferative Disorders with Cyclin Dependent Kinase Inhibitors. Exp. Opin. Ther. Pat. 2000, 10, 215-230.
10. (j) Shapiro, G. I.; Harper, J. W. Anticancer Drug Targets: Cell Cycle and Checkpoint Control J. Clin. Invest. 1999, 104, 1645-1653.
11. (k) Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. ATP-Site Directed Inhibitors of Cyclin-Dependent Kinases. Curr. Med. Chem. 1999, 6, 859-875.
12. (l) Garrett, M. D.; Fattaey, A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 1999, 9, 104-111.
13. (a) Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido-[2,3-d]-pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
14. (b) Fry, D. W.; Bedford, D. C.; Harvey, P. H.; Fritsch, A.; Keller, P. R.; Wu, Z.; Dobrusin, E.; Leopold, W. R.; Fattaey, A.; Garrett, M. D. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 2001, 276, 16617-16623.
15. (c) Toogood, P. L. Cyclin-Dependent Kinase Inhibitors for Treating Cancer. Med. Res. Rev. 2001, 21, 487-498.
16. (a) Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
17. (b) Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S.-H. Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
18. (c) Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, P.; Ludwig, O.; Grierson, D. S.; Leost, M.; Meijer, L.; Endicott, J. Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2-Inhibitor Complex. J. Med. Chem. 2000, 43, 1282-1292.
19. (d) Wang, S.; McClue, S. J.; Ferguson, J. R.; Hull, J. D.; Stokes, S.; Parsons, S.; Westwood, R.; Fischer, P. M. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry 2001, 12, 2891-2894.
20. (e) Chang, Y.-T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
21. (f) Imbach, P.; Capraro, H.-G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-Trisubstituted Purines: Optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 91-96.
22. (g) Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors. Science 1998, 281, 533-538.
23. (h) Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Shiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and Activity of 2,6,9-Trisubstituted Purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
24. (i) Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiftman, D. CVT-313, A Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation. The J. Biol. Chem. 1997, 272, 29207-29211.
25. (j) Havlíček, L.; Hanuš, J.; Veselý, J.; Leclerc, S.; Meijer, L.; Shaw, G.; Strnad, M. Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds. J. Med. Chem. 1997, 40, 408-412.
26. (k) Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J.-G.; Moulinoux, J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhihibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
27. (l) Veselý, J.; Havliček, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.-Y.; Detivaud, L.; LeClerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
28. (a) Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A. M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and Initial Characterization of the Paullones, a Novel Class of Small-Molecule Inhibitors of Cyclin-dependent Kinases. Cancer Res. 1999, 59, 2566-2569.
29. (b) Gussio, R.; Zaharevitz, D. W.; McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.; Meijer, L.; Sausville, E. A. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anti-Cancer Drug Des. 2000, 15, 53-66.
30. (c) Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted Paullones: CDK1/Cyclin B-Inhibiting Property and In Vitro Antiproliferative Activity. Bioorg. Med. Chem. Lett. 2000, 10, 567-569.
31. (d) Schultz, C.; Link, A.; Loest, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, A Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity. J. Med. Chem. 1999, 42, 2909-2919.
32. (e) Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Loest, M.; Meijer, L. 2-Substituted Paullones: CDK1/Cyclin B-Inhibiting Property and In Vitro Antiproliferative Activity. Bioorg. Med. Chem. Lett. 2000, 10, 567-569.
33. (a) Sayle, K. L; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Parsons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-Based Design of 2-Arylamino-4- cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
34. (b) Anderson, M.; Beattie, J. F.; Breault, G. A.; Breed, J.; Byth, K. F.; Culshaw, J. D.; Ellston, R. P. A.; Green, S.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Stanway, J.; Thomas, A. P.; Jewsbury, P. J. Imidazo[1,2-a] pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Indentified Through Structure-Based Hybridisation. Bioorg. Med. Chem. Lett. 2003, 13, 3021-3026.
35. (c) Tang, J.; Shewchuk, L. M.; Sato, H.; Hasegawa, M.; Washio, Y.; Nishigaki, N. Anilinopyrazole as Selective CDK2 Inhibitors: Design, Synthesis, Biological Evaluation, and X-ray Crystallographic Analysis. Bioorg. Med. Chem. Lett. 2003, 13, 2985-2988.
36. (d) Misra, R. N.; Xiao, H.; Rawlins, D. B.; Shan, W.; Kellar, K. A.; Mulheron, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball, S. D.; Webster, K. R. 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases: Highly Potent 2,6-Difluorophenacyl Analogues. Bioorg. Med. Chem. Lett. 2003, 13, 2405-2408.
37. (e) Misra, R. N.; Rawlins, D. B.; Xiao, H.; Shan, W.; Bursuker, I.; Kellar, K. A.; Mulheron, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball, S. D.; Webster, K. R. 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 2003, 13, 1133-1136.
38. (f) Mesguiche, V.; Parsons, R. J.; Arris, C. E.; Bentley, J.; Boyle, F. T.; Curtin, N. J.; Davies, T. G.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Newell, D. R.; Noble, M. E. M.; Wang, L. Z.; Hardcastle, I. R. 4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 217-222.
39. (g) Song, Y.; Wang, J.; Teng, S. F.; Kesuma, D.; Deng, Y.; Duan, J.; Wang, J. H.; Qi, R. Z.; Sim, M. M. β-Carbolines as Specific Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 2002, 12, 1129-1132.
40. (h) Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H.-Y.; Lu, S.; Qian, L.; Han, W.-C.; Shan, W.; Mitt, T.; Cai, Z.-W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. J. Med. Chem. 2002, 45, 3905-3927.
41. (i) Ortega, M. A.; Montoya, M. E.; Zarranz, B.; Jaso, A.; Aldana, I.; Leclerc, S.; Meijer, L.; Monge, A. Pyrazolo[3,4-b]quinoxalines. A New Class of Cyclin-Dependent Kinases Inhibitors, Bioorg. Med. Chem. Lett. 2002, 10, 2177-2184.
42. (j) Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J.-M. Structure-Based Design and Protein X-ray Analysis of a Protein Kinase Inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 221-224.
43. (k) Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. Science 2001, 291, 134-137.
44. (l) Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C.-H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as Cyclin Dependent Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
45. (m) Furet, P.; Meyer, T.; Mittl, P.; Fretz, H. Identification of cyclin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. J. Comput.-Aided Mol. Des. 2001, 15, 489-495.
46. (n) Sasaki, S.; Hashimoto, T.; Obana, N.; Yasuda, H.; Uehara, Y.; Maeda, M. Design of New Inhibitors for CDC2 Kinase Based on a Multiple Pseudosubstrate Structure. Bioorg. Med. Chem. Lett. 1998, 8, 1019-1022.
47. (o) Seong, Y.-S.; Min, C.; Li, L.; Yang, J. Y.; Kim, S.-Y.; C, X.; Kim, K.; Yuspa, S. H.; Chung, H.-H.; Lee, K. S. Characterization of a Novel Cyclin-Dependent Kinase 1 Inhibitor, BMI-1026. Cancer Res. 2003, 63, 7384-7391.
48. (p) Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J.-M.; Meijer, L. Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. J. Med. Chem. 2003, 46, 222-236.
49. (a) Murthi, K. K; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M. D.; Worland, P. J.; Mansuri, M. M.; Pal, K. Structure-Activity Relationship Studies of Flavopiridol Analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-1041.
50. (b) Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effects. J. Med Chem. 2000, 43, 4126-4134.
51. (c) Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Loest, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese anti-leukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
52. (d) Meijer, L.; Thunnissen, A.-M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L.-H., Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
53. (a) Li, X.; Huang, P.; Cui, J. J.; Zhang, J.; Tang, C. Novel Pyrrolyllactone and Pyrrolyllactam Indolinones as Potent Cyclin-Dependent Kinase 2 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1939-1942.
54. (b) Liu, J.-J.; Dermatakis, A.; Lukacs, C.; Konzelmann, F.; Chen, Y.; Kammlott, U.; Depinto, W.; Yang, H.; Yin, X.; Chen, Y.; Schutt, A.; Simcox, M. E.; Luk, K.-C. 3,5,6-Trisubstituted Naphthostyrils as CDK2 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2465-2468.
55. (c) Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. J. Med. Chem. 2001, 44, 4339-4358.
56. (d) Yue, E. W.; Higley, C. A.; DiMeo, S. V.; Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton, C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C.-H.; Seitz, S. P.; Trainor, G. L. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3.Structure Activity Relationships at C3. J. Med. Chem. 2002, 45, 5233-5248.
57. (e) Nugiel, D. A.; Vidwans, A.; Etzkorn, A.-M.; Rossi, K. A.; Benfield, P. A.; Burton, C. R.; Cox, S.; Doleniak, D.; Seitz, S. P. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern. J. Med. Chem. 2002, 45, 5224-5232.
58. (f) Nugiel, D. A.; Etzkorn, A.-M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. P. Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors. J. Med. Chem. 2001, 44, 1334-1336.
59. (g) Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A Novel cdk2-selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells. Cancer Res. 2001, 61, 6170-6177.
60. (h) Andreani, A.; Cavalli, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Recanatini, M.; Garnier, M.; Meijer, L. Imidazo[2,1-b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK/cyclin B inhibition. Anti-Cancer Drug Des. 2000, 15, 447-452.
61. (a) Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 1: Identification and Optimisation of Substituted 4,6-Bis Anilino Pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960.
62. (b) Breault, G. A.; Ellston, R. P. A.; Green, S.; James, S. R.; Jewsbury, P. J.; Midgley, C. J.; Pauptit, R. A.; C. A.; Minshull, Tucker, J. A.; Pease, J. E. Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 2: Identification as Optimisation of Substituted 2,4-Bis Anilino Pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2961-2966.
63. (c) Sanchez-Martinez, C.; Shih, C.; Faul, M. M.; Zhu, G.; Paal, M.; Somoza, C.; Li, T.; Kumrich, C. A.; Winneroski, L. L.; Xun, Z.; Brooks, H. B.; Patel, B. K. R.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Considine, E.; Dempsey, J. A.; Ogg, C. A.; Campbell, R. M.; Anderson, B. A.; Wagner, J. Aryl[a]pyrrolo[3,4,-c]carbazoles as Selective Cyclin D1-CDK4 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3835-3839.
64. (d) Sanchez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H. B.; Patel, B. K. R.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Ogg, C. A.; Considine, E.; Dempsey, J. A.; Zhang, F. Studies on Cyclin-Dependent Kinase Inhibitors: Indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus Bisindolylmaleimides. Bioorg. Med. Chem. Lett. 2003, 13, 3841-3846.
65. (e) Engler, T. A.; Furness, K.; Malhotra, S.; Sanchez-Martinez, C.; Shih, C.; Xie, W.; Zhu, G.; Zhou, X.; Conner, S.; Faul, M. M.; Sullivan, K. A.; Kolis, S. P.; Brooks, H. B.; Patel, B.; Schultz, R. M.; DeHahn, T. B.; Kirmani, K.; Spencer, C. D.; Watkins, S. A.; Considine, E. L.; Dempsey, J. A.; Ogg, C. A.; Stamm, N. B.; Anderson, B. D.; Campbell, R. M.; Vasudevan, V.; Lytle, M. L. Novel, Potent and Selective Cyclin D1/CDK4 Inhibitors: Indolo[6,7-a]pyrrolo[3,4- c]carbazoles. Bioorg. Med. Chem. Lett. 2003, 13, 2261-2267.
66. (f) Zhu, G.; Conner, S.; Zhou, X.; Shih, C.; Brooks, H. B.; Considine, E.; Dempsey, J. A.; Ogg, C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis of Quinolinyl/Isoquinolinyl[a]pyrrolo[3,4-c] Carbazoles as Cyclin D1/CDK4 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1231-1235.
67. (g) Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Fabbro, D.; Chaudhuri, B. Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4. J. Natl. Cancer Inst. 2001, 93, 436-446.
68. (h) Carini, D. J.; Kaltenbach, R. F., III; Liu, J.; Benfield, P. A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C. R.; Cox, S.; Grafstrom, R.; Harrison, B. A.; Harrison, K.; Akamike, E.; Markwalder, J. A.; Nakano, Y.; Seitz, S. P.; Sharp, D. M.; Trainor, G. L.; Sielecki, T. M. Identification of Selective Inhibitors of Cyclin Dependent Kinase 4. Bioorg. Med. Chem. Lett. 2001, 11, 2209-2211.
69. (i) Ryu, C.-K.; Kang, H.-Y.; Lee, S. K.; Nam, K. A.; Hong, C. Y.; Ko, W.-G.; Lee, B.-H. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as Inhibitors of Cyclin-Dependent Kinase 4 and Cytotoxic Agents. Bioorg. Med. Chem. Lett. 2000, 10, 461-464.
70. (j) Honma, T.; Hayaski, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 2001, 44, 4615-4627.
71. (k) Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Moroshima, H. A Novel Approach for the Development of Selective Cdk4 Inhibitors: Library Design Based on Locations of Cdk4 Specific Amino Acid residues. J. Med. Chem. 2001, 44, 4628-4640.
72. (l) Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product. Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
73. (m) Jeong, H.-W.; Kim, M.-R.; Son, K.-H.; Han, M. Y.; Ha, J.-H.; Garnier, M.; Meijer, L.; Kwon, B.-M. Cinnamaldehydes Inhibit Cyclin Dependent Kinase 4/Cyclin D1. Bioorg. Med. Chem. Lett. 2000, 10, 1819-1822.
74. (n) Zhu, G.; Conner, S. E.; Zhou, X.; Shih, C.; Li, T.; Anderson, B. D.; Brooks, H. B.; Campbell, R. M.; Considine, E.; Dempsey, J. A.; Faul, M. M.; Ogg, C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis, Structure-Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors. J. Med. Chem. 2003, 46, 2027-2030.
75. (a) Malumbres, M.; Barbacid, M. To cycle or Not to Cycle: a Critical Decision in Cancer. Nat. Rev. Cancer 2001, 1, 222-231.
76. (b) Kaelin, W. G., Jr. Alterations in G1/S Cell-Cycle Control Contributing to Carcinogenesis. Ann. N. Y. Acad. Sci. 1997, 833, 29-33.
77. (c) Bartek, J.; Lukas, J.; Bartkova, J. The Specificities of Protein Kinase Inhibitors: An Update. Biochem. J. 2003, 371, 199-204.
78. (d) Bartkova, J.; Lukas, J.; Bartek, J. Abberations of the G1- and G1/S-Regulating Genes in Human Cancer. Prog. Cell Cycle Res. 1997, 3, 211-220.
79. (e) Hall, M.; Peters, G. Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in human Cancer. Adv. Cancer Res. 1998, 68, 67-108.
80. (f) Sellers, W. R.; Kaelin, W. G., Jr. Role of the Retinoblastoma Protein in the Pathogenesis of Human Cancer. J. Clin Oncol. 1997, 15, 3301-3312.
81. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, J. K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In Vitro and IN Vivo Antitumor Properties of the Cyclin Dependent Kinase Inhibitor CYC202 (R-Roscovitine). Int. J. Cancer 2002, 102, 463-468.
82. Misra, R. N.; Xiao, H.; Kim, K. S.; Lu, S.; Han, W.-C.; Barbosa, S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B.-C.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S. A.; Sack, J. S.; Tokarski, J. S.; Pavletich, N. P.; Lee, F. Y. F.; Webster, K. R.; Kimball, S. D. N-(Cycloalkylmino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl] -4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent. J. Med. Chem. 2004, 47, 1719-1728.
83. (a) Senderowicz, A. The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings wit the Small Molecule Inhibitors Flavopiridol and UCN-01. The Oncologist 2002, 7 (suppl 3), 12-19.
84. (b) Kelland, L. R. Flavopiridol, the First Cyclin-Dependent Kinase Inhibitors to Enter the Clinic: Current Status. Exp. Opin. Invest. Drugs 2000, 9, 2903-2911.
85. (a) Chao, S.-H.; Price, D. H. Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo. J. Biol. Chem. 2001, 276, 31793-31799.
86. (b) Chao, S.-H.; Fujinaga, K.; Marion, J.; Taube, R.; Sausville, E.; Senderowicz, A.; Peterlin, B. M.; Price, D. H. Flavopiridol Inhibits P-TEFb and Blocks HIV Replication. J. Biol. Chem. 2000, 275, 28345-28348.
87. Sausville, E. Complexities in the Development of Cyclin-Dependent Kinase Inhibitor Drugs. Trends Mol. Med. 2002, 8, S32-S37.
88. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J. L.; Malumbres, M.; Barbacid. Cyclin-Dependent Kinase 2 is Essential for Meiosis but not for Mitotic Cell Division in Mice. Nat. Genet 2003, 35, 25-31.
89. Tetsu, O.; McCormick, F. Proliferation of Cancer Cells Despite CDK2 Inhibition. Cancer Cell 2003, 2, 233-245.
90. Fry, D. W.; Harvey, P. J.; Keller, P. R.; Elliott, W. L.; Meade, M. A.; Trachet, E.; Albassam, M.; Zheng, X.; Leopold, W. R.; Pryer, N. K.; Toogood, P. L. Specific Inhbition of Cyclin-Dependent Kinase 4/6 by PD 0332991 and Associated Antitumor Activity in Human Tumor Xenografts. Mol. Cancer Ther. 2004, 3, 1427-1437.
91. VanderWel, S. N.; Harvey, P. J.; McNamara, D. J.; Repine, J. T.; Keller, P. R.; Quin, J., III; Booth, R. J.; Elliott, W. R.; Dobrusin, E. M.; Fry, D. W.; Toogood, P. L. Pyrido[2,3-d]-pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4. J. Med. Chem. 2005, 48, 2371-2387.
92. Booher, R. N.; Holman, P. S.; Fattaey, A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J. Biol. Chem. 1997, 272, 22300-22306.
93. Meyerson, M.; Harlow, E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol. 1994, 14, 2077-2086.
94. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
95. Fry, D. W.; Kraker, A. J.; Connors, R. C.; Elliott, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des. 1994, 9, 331-351.
96. Fry, D. W.; Nelson, J. M.; Slintak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, H.; Bridges, A. J. Biomedical and antiproliferative properties of 4-[(ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1997, 54, 877-887.